NEWS | BEAM Alliance


Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds

UNION, N.J., May 21, 2019 /PRNewswire/ — Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into an exclusive licensing agreement with Fundación MEDINA, the not-for-profit Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia.

Full PR available here